Примери за използване на Prolonged release suspension на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Prolonged release suspension for injection.
One vial of powder for prolonged release suspension for injection.
Prolonged release suspension for injection 1 pre-filled syringe.
Powder and solvent for prolonged release suspension for injection.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer Carton ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection.
ZYPADHERA powder for prolonged release suspension for injection comes as a yellow powder in a clear glass vial.
Outer Carton ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection.
Because the medicine is a prolonged release suspension, it also has the advantage of being given at monthly intervals.
NAME OF THE MEDICINAL PRODUCT ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection Olanzapine.
Reconstitute ZYPADHERA powder for prolonged release suspension for injection only with the solvent provided in the pack using standard aseptic techniques for reconstitution of parenteral products.
ZYPADHERA is a powder and solvent for prolonged release suspension for injection.
TREVICTA 175 mg prolonged release suspension for injection TREVICTA 263 mg prolonged release suspension for injection TREVICTA 350 mg prolonged release suspension for injection TREVICTA 525 mg prolonged release suspension for injection.
Xeplion 150 mg andXeplion 100 mg prolonged release suspension for injection.
Determining solvent volume for reconstitution This table provides the amount of solvent required to reconstitute ZYPADHERA powder for prolonged release suspension for injection.
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection Olanzapine.
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection.
Vial Label ZYPADHERA 210 mg powder for prolonged release suspension for injection.
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 300 mg powder and solvent for prolonged release suspension for injection ZYPADHERA 405 mg powder and solvent for prolonged release suspension for injection.
This table provides the amount of solvent required to reconstitute ZYPADHERA powder for prolonged release suspension for injection.
Do not confuse ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection with olanzapine 10 mg powder for solution for injection.
What ZYPADHERA looks like and contents of the pack One carton contains one vial of powder for prolonged release suspension for injection and one vial of 3 ml solvent.
One carton contains one vial of powder for prolonged release suspension for injection, one vial of 3 ml solvent, one syringe with safety needle, 19 gauge, 38mm, attached and three separate safety needles; one 19 gauge, 38mm needle and two 19 gauge 50mm needles.
What Xeplion looks like and contents of the pack Xeplion is a white to off-white prolonged release suspension for injection in a pre-filled syringe.
ZYPADHERA 210 mg, 300 mg or 405 mg powder and solvent for prolonged release suspension for injection must not be confused with olanzapine 10 mg powder for solution for injection.
What ZYPADHERA looks like andcontents of the pack ZYPADHERA powder for prolonged release suspension for injection comes as a yellow powder in a clear glass vial.
What TREVICTA looks like and contents of the pack TREVICTA is a white to off-white prolonged release suspension for injection in a pre-filled syringe that your doctor or nurse will shake vigorously to resuspend the suspension before it is given as an injection.
Prolonged release powder and solvent for suspension for injection.
Prolonged release powder and solvent for suspension for injection.
It is available as prolonged release powder and solvent for suspension for intramuscular use.
Therefore, pursuant to Article 116 of Directive 2001/83/EC,the CMDh recommends the suspension of the marketing authorisations for products containing paracetamol, modified and prolonged release.